Zervimesine (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name; developmental code name CT-1812 or CT1812) is a sigma σ2 receptor antagonist which is under development for the treatment of Alzheimer's disease, dementia, dry age-related macular degeneration, and other indications. The drug shows high affinity for the sigma σ2 receptor (Ki = 8.5 nM). It also shows 7.4-fold lower affinity for the sigma σ1 receptor (Ki = 63 nM). Aside from the sigma σ1 receptor, the drug shows 100-fold selectivity for the sigma σ2 receptor over 72 other targets. The sigma σ2 receptor is a binding site for β-amyloid oligomers. Zervimesine has been found to diplace β-amyloid oligomers from the sigma σ2 receptor in both preclinical and clinical studies. As of 2024, effectiveness data on zervimesine for treatment of Alzheimer's disease are still lacking. Zervimesine is under development by Cognition Therapeutics. As of July 2025, it is in phase 2 clinical trials for Alzheimer's disease, dementia with Lewy bodies (DLB), and dry age-related macular degeneration. The drug was also being developed for treatment of other cognitive disorders, but development for this indication was discontinued.
See also List of investigational cognition and memory disorder drugs Blarcamesine
References

